

Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

<p>Substitute for form 1449/PTO</p> <p>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				<p><i>Complete if Known</i></p> <table border="1"> <tr> <td>Application Number</td> <td>10/765,568</td> </tr> <tr> <td>Filing Date</td> <td>January 28, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>CHANG, Esther H.</td> </tr> <tr> <td>Art Unit</td> <td>1642</td> </tr> <tr> <td>Examiner Name</td> <td>HALVORSON, M.</td> </tr> <tr> <td colspan="2">Attorney Docket Number</td> </tr> </table>		Application Number	10/765,568	Filing Date	January 28, 2004	First Named Inventor	CHANG, Esther H.	Art Unit	1642	Examiner Name	HALVORSON, M.	Attorney Docket Number	
Application Number	10/765,568																
Filing Date	January 28, 2004																
First Named Inventor	CHANG, Esther H.																
Art Unit	1642																
Examiner Name	HALVORSON, M.																
Attorney Docket Number																	
Sheet	1	of	1	2474.0100001/BJD/JKM													

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


649369v1

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-08)

Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet 1 of 5				Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/MH/	NPL1	ABOUNADER, R., <i>et al.</i> , "In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis," <i>FASEB J.</i> 16:108-110, Federation of American Societies for Experimental Biology (January 2002)	
	NPL2	ALLEN, T.M., <i>et al.</i> , "A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells," <i>Biochim. Biophys. Acta</i> 1237:99-108, Elsevier Science Inc. (1995)	
	NPL3	ALLEN, T.M., <i>et al.</i> , "Antibody-Targeted Stealth Liposomes" in <i>Stealth Liposomes</i> , Lasic, D.D. and Martin, F.J., eds., CRC Press Inc., Boca Raton, FL, pp. 233-244 (1995)	
	NPL4	AOKI, K., <i>et al.</i> , "Liposome-mediated <i>in Vivo</i> Gene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity," <i>Cancer Res.</i> 55:3810-3816, American Association for Cancer Research (1995)	
	NPL5	BANNERJI, R., <i>et al.</i> , "Campath-1H antibody induces transmembrane signaling <i>in vitro</i> and <i>in vivo</i> in patients with chronic lymphocytic leukemia (CLL) and promotes tumor clearance in part through caspase mediated apoptosis," <i>Blood</i> 98:808a, American Society of Hematology (2001)	
	NPL6	BYRD, J.C., <i>et al.</i> , "The mechanism of tumor cell clearance by rituximab <i>in vivo</i> in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction," <i>Blood</i> 99:1038-1043, American Society of Hematology (February 2002)	
	NPL7	CHENG, P.-W., "Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin," <i>Human Gene Ther.</i> 7:275-282, Mary Ann Liebert, Inc. (1996)	
	NPL8	CRISTIANO, R.J. and CURIEL, D.T., "Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway," <i>Cancer Gene Ther.</i> 3:49-57, Nature Publishing Group (1996)	
	NPL9	CRYNS, V. and YUAN, J., "Proteases to die for," <i>Gene Dev.</i> 12:1551-1570, Cold Spring Harbor Laboratory Press (1998)	
↓	NPL10	ELLIOTT, R.L., <i>et al.</i> , "Breast Carcinoma and the Role of Iron Metabolism: A Cytochemical, Tissue Culture, and Ultrastructural Study," <i>Ann. N. Y. Acad. Sci.</i> 698:159-166, New York Academy of Sciences (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	2	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
/MH/	NPL11	ESTROV, Z., et al., "Caspase 2 and Caspase 3 Protein Levels as Predictors of Survival in Acute Myelogenous Leukemia," <i>Blood</i> 92:3090-3097, American Society of Hematology (1998)			
	NPL12	EVAN, G.I. and VOUSDEN, K.H., "Proliferation, cell cycle and apoptosis in cancer," <i>Nature</i> 411:342-348, Nature Publishing Group (2001)			
	NPL13	FELGNER, P.L., et al., "Improved Cationic Lipid Formulations for <i>In Vivo</i> Gene Therapy," <i>Ann. N. Y. Acad. Sci.</i> 772:126-139, New York Academy of Sciences (1995)			
	NPL14	FENNELL, D.A., et al., "In vivo suppression of Bcl-X _L expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model," <i>Brit. J. Haematol.</i> 112:706-713, Blackwell Science Ltd. (2001)			
	NPL15	HANAHAN, D. and WEINBERG, R.A., "The Hallmarks of Cancer," <i>Cell</i> 100:57-70, Cell Press (2000)			
	NPL16	HAYAMI, S., et al., "Increase of Caspase-3 Activity in Rat Liver and Plasma by Thioacetamide," <i>Biochem. Pharmacol.</i> 58:1941-1943, Elsevier Science Inc. (1999)			
	NPL17	HAYAMI, S., et al., "Change in Caspase-3-Like Protease in the Liver and Plasma during Rat Liver Regeneration Following Partial Hepatectomy," <i>Biochem. Pharmacol.</i> 60:1883-1886, Elsevier Science Inc. (2000)			
	NPL18	HORVITZ, H.R., "Genetic Control of Programmed Cell Death in the Nematode <i>Caenorhabditis elegans</i> ," <i>Cancer Res.</i> 59:1701s-1706s, American Association for Cancer Research (1999)			
	NPL19	HUWYLER, J., et al., "Brain drug delivery of small molecules using immunoliposomes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:14164-14169, National Academy of Sciences (1996)			
▼	NPL20	JÄÄTELÄ, M., "Escaping Cell Death: Survival Proteins in Cancer," <i>Exp. Cell Res.</i> 248:30-43, Academic Press (1999)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	3	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			
/MH/	NPL21	JACOBSON, M.D., et al., "Programmed Cell Death in Animal Development," <i>Cell</i> 88:347-354, Cell Press (1997)			
	NPL22	JIANG, A., et al., "Cell-Type-Specific Gene Transfer into Human Cells with Retroviral Vectors That Display Single-Chain Antibodies," <i>J. Virol.</i> 72:10148-10156, American Society For Microbiology (1998)			
	NPL23	KITADA, S., et al., "The Mechanism of <i>In Vivo</i> Leukemia Cell Clearance by Rituximab in Patients with CLL Involves Apoptosis by a Caspase 9 Pathway," <i>Blood</i> 96:515a, Abstract No. 2216, American Society of Hematology (2000)			
	NPL24	KÖHLER, C., et al., "Evaluation of caspase activity in apoptotic cells," <i>J. Immunol. Methods</i> 265:97-110, North-Holland Pub. Co. (July 2002)			
	NPL25	KONISHI, H., et al., "Targeting Strategy for Gene Delivery to Carcinoembryonic Antigen-Producing Cancer Cells by Retrovirus Displaying a Single-Chain Variable Fragment Antibody," <i>Human Gene Ther.</i> 9:235-248, Mary Ann Liebert (1998)			
	NPL26	LEE, R.J. and HUANG, L., "Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer," <i>J. Biol. Chem.</i> 271:8481-8487, American Society for Biochemistry and Molecular Biology (1996)			
	NPL27	LEWIS, J.G., et al., "A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:3176-3181, National Academy of Sciences (1996)			
	NPL28	MANCINI, M., et al., "The Caspase-3 Precursor Has a Cytosolic and Mitochondrial Distribution: Implications for Apoptotic Signaling," <i>J. Cell Biol.</i> 140:1485-1495, Rockefeller University Press (1998)			
	NPL29	MARTIN, F., et al., "Retroviral Vector Targeting to Melanoma Cells by Single-Chain Antibody Incorporation in Envelope," <i>Human Gene Ther.</i> 9:737-746, Mary Ann Liebert (1998)			
▼	NPL30	MASSING, U., "Cancer therapy with liposomal formulations of anticancer drugs," <i>Int. J. Clin. Pharmacol. Ther.</i> 35:87-90, Dustri-Verlag Dr. K. Feistel (1997)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known .</i>	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet		4	of	5	Attorney Docket Number
					2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
/MH/	NPL31	MATHIASSEN, I.S. and JÄÄTTELÄ, M., "Triggering caspase-independent cell death to combat cancer," <i>Trends Mol. Med.</i> 8:212-220, Elsevier Science Ltd. (April 2002)			
	NPL32	MIYAMOTO, T., et al., "Transferrin receptor in oral tumors," <i>Int. J. Oral Maxillofac. Surg.</i> 23:430-433, Munksgaard (1994)			
	NPL33	NAWROCKI, S.T., et al., "Effects of the Proteasome Inhibitor PS-341 on Apoptosis and Angiogenesis in Orthotopic Human Pancreatic Tumor Xenografts," <i>Molec. Cancer Ther.</i> 1:1243-1253, American Association for Cancer Research, Inc. (December 2002)			
	NPL34	NICHOLSON, D.W. and THORNBERRY, N.A., "Caspases: killer proteases," <i>Trends Biochem. Sci.</i> 22:299-306, Elsevier Science Ltd. (1997)			
	NPL35	NICHOLSON, I.C., et al., "Construction and Characterisation of a Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukaemia and Lymphoma," <i>Mol. Immunol.</i> 34:1157-1165, Pergamon Press (1997)			
	NPL36	NUÑEZ, G., et al., "Caspases: the proteases of the apoptotic pathway," <i>Oncogene</i> 17:3237-3245, Nature Publishing Group (1998)			
	NPL37	PARK, J.W., et al., "Development of anti-p185 ^{HER2} immunoliposomes for cancer therapy," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92:1327-1331, National Academy of Sciences (1995)			
	NPL38	POON, R.Y.M., "Advances in Monoclonal Antibody Applications: Bispecific Antibodies" in <i>Biotechnology International: International Developments in the Biotechnology Industry</i> , Fox, F. and Connor, T.H., eds., Universal Medical Press, Inc., San Francisco, CA, pp. 113-128 (1997)			
	NPL39	SUN, F., et al., "Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver," <i>Biochim. Biophys. Acta</i> 1500:181-185, Elsevier Science B.V. (2000)			
▼	NPL40	SUN, F., et al., "Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver," <i>Biochim. Biophys. Acta</i> 1535:186-191, Elsevier Science B.V. (2001)			
Examiner Signature		Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	5	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
/MH/	NPL41	SUN, F., et al., "Evaluation of oxidation stress during apoptosis and necrosis caused by D-galactosamine in rat liver," <i>Biochem. Pharmacol.</i> 65:101-107, Elsevier Science Inc. (January 2003)				
	NPL42	SUZUKI, S., et al., "Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor," <i>Br. J. Cancer</i> 76:83-89, Nature Publishing Group (1997)				
	NPL43	THIERRY, A.R., et al., "Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92:9742-9746, National Academy of Science (1995)				
	NPL44	THORSTENSEN, K. and ROMSLO, I., "The Transferrin Receptor: Its Diagnostic Value and its Potential as Therapeutic Target," <i>Scand. J. Clin. Lab. Invest. Suppl.</i> 215:113-120, Universitetsforlaget (1993)				
↓	NPL45	WHITACRE, C.M., et al., "Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4 of SW480 Human Colon Cancer Xenografts in Athymic Mice," <i>Clin. Cancer. Res.</i> 6:2021-2027, American Association for Cancer Research (2000)				

587436v1

Examiner Signature	/Mark Halvorson/	Date Considered	12/05/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.